Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, International, Multicenter, Single-arm, Uncontrolled, Phase IIIb Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Demonstrate an Insufficient Response to Treatment With Approved Dosages of Phosphodiesterase-5 Inhibitors (PDE-5i)

Trial Profile

An Open-label, International, Multicenter, Single-arm, Uncontrolled, Phase IIIb Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Demonstrate an Insufficient Response to Treatment With Approved Dosages of Phosphodiesterase-5 Inhibitors (PDE-5i)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms RESPITE
  • Sponsors Bayer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Apr 2018 Results of post-hoc analysis of switching from PDE5i to Riociguat in the RESPITE study, presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
    • 01 Sep 2017 Primary endpoint (Change from baseline in 6 minute walking distance) has been met, according to the results published in the European Respiratory Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top